Tech Company Financing Transactions

CytomX Therapeutics Funding Round

CytomX Therapeutics, based in San Francisco, secured $20 million in investment from Pfizer Venture Investments, Canaan Partners and Roche Venture Fund.

Transaction Overview

Company Name
CytomX Therapeutics
Announced On
1/6/2015
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series C
Investors

Pfizer Venture Investments (Lead Investor) (Elaine Jones)

Canaan Partners (Timothy Shannon)

Roche Venture Fund

Third Rock Ventures (Neil Exter)

Proceeds Purpose
The proceeds from this financing will help enable CytomX to advance our proprietary pipeline of Probody Drug Conjugates and Probodies against cancer immunotherapy checkpoint targets towards the clinic, while we also pursue Probody applications with bispecific antibodies and engineered T-cell therapies.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 400
San Francisco, CA 94080
USA
Phone
(650) 515-3185
Website
www.cytomx.com
Email Address
[email protected]
Overview
CytomX (NASDAQ: CTMX) is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics.
Profile
CytomX Therapeutics LinkedIn Company Profile
Social Media
CytomX Therapeutics Company Twitter Account
Company News
CytomX Therapeutics News
Facebook
CytomX Therapeutics on Facebook
YouTube
CytomX Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Sean McCarthy
  Sean McCarthy LinkedIn Profile  Sean McCarthy Twitter Account  Sean McCarthy News  Sean McCarthy on Facebook
Chief Scientific Officer
Michael Kavanaugh
  Michael Kavanaugh LinkedIn Profile  Michael Kavanaugh Twitter Account  Michael Kavanaugh News  Michael Kavanaugh on Facebook
Vice President
Alison Joly
  Alison Joly LinkedIn Profile  Alison Joly Twitter Account  Alison Joly News  Alison Joly on Facebook
VP - Human Resources
Danielle Olander
  Danielle Olander LinkedIn Profile  Danielle Olander Twitter Account  Danielle Olander News  Danielle Olander on Facebook
VP - Manufacturing
Sridhar Viswanathan
  Sridhar Viswanathan LinkedIn Profile  Sridhar Viswanathan Twitter Account  Sridhar Viswanathan News  Sridhar Viswanathan on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/6/2015: IntroHive venture capital transaction
Next: 1/6/2015: Batanga venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.